Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Stargardt Disease

Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Stargardt disease is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. The disease causes progressive damage — or degeneration — of the macula, which is a small area in the center of the retina that is responsible for sharp, straight-ahead vision. In most cases, Stargardt macular degeneration is caused by mutations in the ABCA4 gene. Less often, mutations in the ELOVL4 gene cause this condition. The ABCA4 and ELOVL4 genes provide instructions for making proteins that are found in light-sensing (photoreceptor) cells in the retina.

According to Thelansis estimates, Stargardt macular degeneration is the most common form of juvenile macular degeneration, the signs and symptoms of which begin in childhood. The estimated prevalence of Stargardt macular degeneration is 1 in 8,000 to 10,000 individuals.

Competitive landscape of Stargardt Disease includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

Stargardt Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

KOLs insights of Stargardt Disease across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Read more: Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company        Partner        Phase

1        ACU-4429        Kubota Pharmaceutical Holdings Co., Ltd.        N/A        III

2        Zimura        Iveric Bio        Archemix        IIb

3        ALK-001        Alkeus Pharmaceuticals, Inc.        N/A        II

4        ASP7317        Astellas Pharma, Inc.        CHA Bio & Diostech        II

5        LBS-008        Lin Bioscience, Inc.        N/A        I

6        NSR-ABCA4        Biogen, Inc.        N/A        Preclinical

7        QRX-1011        ProQR Therapeutics N.V.        N/A        Preclinical

8        REV-0100        reVision Therapeutics, Inc.        Cornell University        Preclinical

9        Stargardt Program        Applied Genetic Technologies Corporation        N/A        Preclinical

10        STGD1 Minigene Program (IVERIC/UMass)        Iveric Bio        N/A        Preclinical